Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.

Abstract: Methods for cleaning a superalloy substrate having engine deposits on its surface are provided. The method may include applying a permanganate solution onto the surface of the superalloy substrate, and applying a ferric chloride based cleaning composition onto the surface of the superalloy substrate. The ferric chloride based cleaning composition includes ferric chloride and at least one of nitric acid and phosphoric acid, such as within a solvent system (e.g., an aqueous solution including water).

Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.

Abstract: A multiport amplifier MPA is provided with an N-input input network, INET, an N-output output network, ONET, and N amplifiers interposed between the INET and the ONET, the MPA comprising N wanted signal paths and N.(N?1) null signal paths wherein N is divisible by 2, half of the N amplifier paths comprise a signal inversion with respect to the other half of the N amplifier paths, the INET and the ONET each comprise one or more quadrature hybrid couplers, QHC, wherein a pair of amplifier paths is arranged between the output of a first QHC in the INET and the input of a second QHC at the ONET, and each signal inversion is arranged in one of the amplifier paths of each pair of amplifier paths such that the ideal amplitude gain of at least one of the N.(N?i) null signal paths is zero.

Abstract: Certain embodiments are described that provide a battery cell testing fixture. The fixture has a first test housing shaped to hold a plurality of battery cells including a central battery cell and a plurality of surrounding battery cells. The first test housing holds the plurality of battery cells in a desired proximity corresponding to an actual proximity in a production battery cell module containing a lamer number of battery cells. At least one battery test initiation lead element is configured to be engaged to the central battery cell. At least one battery test monitoring lead element configured to be engaged to one of the plurality of surrounding battery cells.

Abstract: A multiport amplifier MPA is provided with an N-input input network, INET, an N-output output network, ONET, and N amplifiers interposed between the INET and the ONET, the MPA comprising N wanted signal paths and N·(N?1) null signal paths wherein N is divisible by 2, half of the N amplifier paths comprise a signal inversion with respect to the other half of the N amplifier paths, the INET and the ONET each comprise one or more quadrature hybrid couplers, QHC, wherein a pair of amplifier paths is arranged between the output of a first QHC in the INET and the input of a second QHC at the ONET, and each signal inversion is arranged in one of the amplifier paths of each pair of amplifier paths such that the ideal amplitude gain of at least one of the N·(N?i) null signal paths is zero.

Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.

Abstract: An indicator device comprises a first slide member (22) mounted on a planar base (1). The first slide member (22) is displaceable between a first position in which it reveals a first status indicating area (26) indicative of a first condition or state and a second position in which it reveals a second status indicating area (28) indicative of a second condition or state. A second slide member (30) is mounted on the base (10) and is displaceable into and across the path of the first indicator member (22) when the first indicator member is in the first position, to inhibit displacement of the first indicator member. The second indicator member (30) is displaceable between a first position in which it does not inhibit the displacement of the first indicator member (22) and a second position in which it inhibits the displacement of the first indicator member to its second position. The device may also be provided with one or more RFID tags (80, 82, 84) to permit remote monitoring of the status of the device.

Abstract: An inhaler for delivering a preferably powdered formulation from a blister strip having a plurality of blister pouches. In order to achieve a compact simple construction for the inhaler and an easy action for the blister strip, the carrier extends over a circumferential angle of the inhaler of less than 360°. In particular, the carrier is guided between two deflectors with an at least substantially constant curvature, and preferably, exclusively along an outer wall of the inhaler. A conveying device of the inhaler has four drive wheels of the same diameter which are arranged on a common radius and are driven by common drive means in the same direction of rotation.

Abstract: Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12R?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.

Abstract: An inhaler for delivering a preferably powdered formulation from a blister strip having a plurality of blister pouches. In order to achieve a compact simple construction for the inhaler and an easy action for the blister strip, the carrier extends over a circumferential angle of the inhaler of less than 360°. In particular, the carrier is guided between two deflectors with an at least substantially constant curvature, and preferably, exclusively along an outer wall of the inhaler. A conveying device of the inhaler has four drive wheels of the same diameter which are arranged on a common radius and are driven by common drive means in the same direction of rotation.

Abstract: A blister piercing element for puncturing the lid of a blister containing a dose of medicament for inhalation by a user. The piercing element has an outlet opening for the passage of medicament entrained in an airflow out of the blister and, a piercing head extending beyond and overhanging the opening that cuts a flap in a lid of a blister and pushes it away from the opening during insertion.

Abstract: The method of attaching a pulling head to two or more wires or cables for installation in a conduit, comprising providing a first area for attaching the pulling head, placing two or more wire or cable supply spools on a first side of the first area, placing a receiving spool on the opposite or second side of the first area, feeding a portion of the wires or cables from the wire or cable supply spools onto the receiving spool, placing a terminating table in the first area below the wires or cables, cutting the wires or cables at staggered length from the receiving spool, stripping a portion of the covering from the wires or cables from the outer diameter of the two or more wires or cables, installing a connection onto each of the two or more wires or cables.

Abstract: The method of attaching a pulling head to two or more wires or cables for installation in a conduit, comprising providing a first area for attaching the pulling head, placing two or more wire or cable supply spools on a first side of the first area, placing a receiving spool on the opposite or second side of the first area, feeding a portion of the wires or cables from the wire or cable supply spools onto the receiving spool, placing a terminating table in the first area below the wires or cables, cutting the wires or cables at staggered length from the receiving spool, stripping a portion of the covering from the wires or cables from the outer diameter of the two or more wires or cables, installing a connection onto each of the two or more wires or cables.

Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.

Abstract: An inhaler comprising a housing defining a chamber to receive a strip having a plurality of blisters each containing a dose of medicament for inhalation by a user is disclosed. It comprises an actuating lever and a blister strip drive member rotatably mounted in the chamber to sequentially move each blister into a blister opening position. The blister strip drive member and the actuating lever comprise a drive gear and a drive gear element, respectively, that cooperate to effect rotation of the blister strip drive member in response to rotation of the actuating lever. The drive gear and drive gear element are disposed on the outside of the housing remote from the chamber.

Abstract: An inhaler is disclosed. It comprises a housing to receive a strip of blisters each having a puncturable lid and containing a dose of medicament for inhalation by a user, a mouthpiece through which a dose of medicament is inhaled by a user and, an actuator operable to sequentially move each blister into alignment with a blister piercing member. The actuator is also operable to cause the blister piercing element to puncture the lid of a blister such that, when a user inhales through the mouthpiece, an airflow through the blister is generated to entrain the dose contained therein and carry it out of the blister and via the mouthpiece into the user's airway.

Abstract: An inhaler comprising a housing to receive a strip having a plurality of blisters is disclosed. Each blister has a puncturable lid and contains a dose of medicament for inhalation by a user. A mouthpiece is pivotally mounted to the housing through which a dose of medicament is inhaled by a user. The inhaler also has an actuating mechanism including a lever operable to sequentially move each blister into alignment with a blister piercing member depending from the mouthpiece. The actuating lever is also operable to cause the mouthpiece to pivot so that the blister piercing member punctures the lid of an aligned blister so that, when a user inhales through the mouthpiece, an airflow through the blister is generated to entrain the dose contained therein and carry it, via the mouthpiece, into the user's airway.

Abstract: Described are methods of preventing, treating and diagnosing of a subject having a condition, such as, an inflammation or infection of the respiratory tract. Methods of treatment and prevention include administration of effective amounts of calcium salt formulations to a subject. Methods of diagnosing include the use of biomarkers and optionally the use of kits that can detect biomarkers. Further described are methods for modulating an immune response that include the modulation of Toll-like receptors.